The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses

Clin Microbiol Infect. 2021 Dec;27(12):1784-1789. doi: 10.1016/j.cmi.2021.07.005. Epub 2021 Jul 10.

Abstract

Background: Both humoral and cell-mediated responses are associated with immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although our understanding of the potential role of T-cell responses in the context of coronavirus disease 2019 (COVID-19) is rapidly increasing, more information is still needed.

Objectives: To provide an overview of the role of T-cell immunity in COVID-19, in the context of natural infection and post-vaccination, and discuss the potential utility of measuring SARS-CoV-2-specific T-cell responses, drawing on experience of the use of interferon-γ release assays (IGRAs) in tuberculosis (TB).

Sources: PubMed articles up to 16 April 2021.

Content: T-cell responses can be detected very early in the course of COVID-19, earlier than the detection of antibody responses, and are correlated with COVID-19 outcome. Lower CD4+ and CD8+ T-cell counts are markers of more severe disease, longer duration of viral RNA positivity and increased mortality. In line with natural infection, SARS-CoV-2 vaccination stimulates robust T-cell responses, which probably play an important role in protection; data on long-term T-cell responses are currently limited. The utility of measuring T-cell responses is already well established in both aiding the diagnosis of TB infection using IGRAs, and evaluation of T-cell responses to TB vaccine candidates. A variety of assays have already been developed to measure SARS-CoV-2-specific T-cell responses, including IGRAs, intracellular cytokine staining and activation-induced markers. IGRAs based on SARS-CoV-2 antigens can distinguish between convalescent and uninfected healthy blood donors.

Implications: Simple assays for measuring the quantity and function of T-cell responses may have utility in the prognostication of COVID-19, and for monitoring immune responses to SARS-CoV-2 vaccination and population-based immunity to SARS-CoV-2 variants of interest.

Keywords: Cellular immunity; Coronavirus disease 2019; Interferon-γ release assay; Severe acute respiratory syndrome coronavirus 2; T cell; Tuberculosis.

Publication types

  • Review

MeSH terms

  • Antibodies, Viral
  • COVID-19 Vaccines
  • COVID-19* / immunology
  • Humans
  • Immunity, Cellular*
  • SARS-CoV-2 / immunology
  • T-Lymphocytes* / immunology

Substances

  • Antibodies, Viral
  • COVID-19 Vaccines

Supplementary concepts

  • SARS-CoV-2 variants